What is the recommended treatment for herpes simplex labial infection (cold sores)?

Treatment of Herpes Simplex Labialis (Cold Sores)

For acute treatment of herpes labialis, initiate oral antiviral therapy as soon as prodromal symptoms begin—preferably valaciclovir 2 g twice daily for 1 day or famciclovir 1500 mg as a single dose—which reduces episode duration by approximately 1 day and decreases pain. 1

Episodic Treatment Approach

First-Line Oral Antivirals (Preferred)

The evidence strongly supports oral antivirals over topical agents for episodic treatment 2. Three options are available:

• Valaciclovir: 2 g twice daily for 1 day (most convenient dosing)

  • Reduces median episode duration from 5.0 days (placebo) to 4.0-5.0 days (p <0.001) 1
  • Superior bioavailability compared to aciclovir 2

• Famciclovir: 1500 mg single dose for 1 day

  • Reduces healing time of primary lesions from 6.6 to 6.2 days (p <0.001) 1
  • Time to return to normal skin: 2.9 days vs 4.5 days with placebo 1

• Aciclovir: 400 mg 5 times daily for 5 days OR 800 mg twice daily for 3-7 days

  • Less convenient dosing but effective
  • Reduces pain duration from 3.9 to 2.5 days (p = 0.02) 1
  • Lower cost but requires more frequent dosing 2

Critical Timing

Treatment must begin within the prodromal stage or within 48 hours of lesion onset to achieve optimal results 2. The brief therapeutic window makes early self-recognition and immediate treatment initiation essential. Delayed treatment significantly reduces efficacy 3.

Topical Antivirals (Alternative, Less Effective)

Topical agents provide modest benefit but are inferior to oral therapy:

• Aciclovir 5% cream: Apply 5 times daily for 4 days

  • Reduces episode duration by approximately 0.5 days (4.3-4.6 days vs 4.8-5.2 days placebo; p = 0.006-0.007) 4
  • Does NOT prevent lesion progression to vesicles/ulcers 4

• Aciclovir 5% + Hydrocortisone 1% cream (Xerese):

  • Reduces both ulcerative and non-ulcerative recurrences 5
  • The corticosteroid component addresses immune-mediated inflammation 5

• Penciclovir 1% cream: Alternative topical option 2

Topical agents are NOT effective for prevention of recurrent episodes 6.

Chronic Suppressive Therapy

Indications

Consider suppressive therapy for patients with:

• ≥6 episodes per year 2
• Severe recurrences
• Significant psychosocial impact

Suppressive Regimens

• Aciclovir: 400 mg twice daily

  • Reduces clinical recurrences by 53% (p = 0.009) 1
  • Extends time to recurrence from 46 to 118 days (p = 0.05) 1

• Valaciclovir: 500 mg once daily

  • 60% of patients remain recurrence-free vs 38% on placebo (p = 0.041) 1
  • Extends mean time to recurrence from 9.6 to 13.1 weeks (p = 0.016) 1

• Famciclovir: Effective for suppression 2, 7

Safety Profile

All three oral antivirals (aciclovir, valaciclovir, famciclovir) demonstrate excellent safety with no increased adverse events compared to placebo 1, 6. Common mild side effects include:

• Headache (<10%)
• Nausea (<4%)
• No serious adverse events reported in clinical trials 1

Important Clinical Considerations

Common Pitfalls to Avoid

1. Delayed treatment initiation: The therapeutic window is narrow—patients must start treatment at first prodromal symptoms (tingling, burning) 2

2. Relying on topical therapy alone: Oral antivirals are significantly more effective 2, 3

3. Inadequate patient education: Patients need to recognize prodromal symptoms and have medication readily available for immediate self-initiation 1

4. Expecting lesion abortion: Antivirals reduce duration and pain but typically do NOT prevent lesion development once initiated 3, 4

Resistance Concerns

Antiviral resistance is uncommon in immunocompetent patients 8. Long-term suppressive therapy in immunocompromised patients poses higher risk, but this is not a concern for typical herpes labialis management in healthy individuals 1, 8.

Practical Implementation

Pharmacy-based access to antivirals improves outcomes by reducing treatment delays 1, 9. Patients can self-initiate therapy immediately upon prodrome recognition rather than waiting for physician appointments. This approach has proven safe in Canada, Australia, New Zealand, and parts of the United States 9.

Adjunctive Measures

• Sunscreen application: May prevent UV-induced recurrences (RR 0.07,95% CI 0.01-0.33) in experimental settings 6
• Condoms and disclosure: Reduce transmission risk during active lesions 7

Clinical Benefit Context

While statistically significant, the absolute clinical benefit is modest—approximately 1 day reduction in episode duration and pain 3. However, for patients experiencing frequent recurrences or significant cosmetic/psychosocial distress, this benefit combined with reduced viral shedding justifies treatment 2, 5.